FDAnews
www.fdanews.com/articles/192952-torrent-pharma-broadens-losartan-potassium-recall

Torrent Pharma Broadens Losartan Potassium Recall

October 3, 2019

Torrent Pharmaceuticals expanded its recall of losartan potassium tablets to the consumer level due to the detection of trace amounts of N-Methylnitrosobutyric acid (NMBA), a probable carcinogen.

The company is only recalling certain lots of losartan-containing products that contained more than the acceptable daily intake levels of NMBA.

The expanded recall included an additional three lots of losartan potassium tablets and two lots of losartan potassium/hydrocholorothiazide tablets.

View today's stories